DCF Advisers’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44.7K Hold
14,700
0.01% 93
2026
Q1
$45.3K Sell
14,700
-4,000
-21% -$17K 0.01% 86
2025
Q4
$67.5K Buy
+18,700
New +$81.5K 0.02% 94
2025
Q3
Sell
-10,770
Closed -$41.7K 97
2025
Q2
$41.7K Sell
10,770
-11,000
-51% -$59.5K 0.02% 82
2025
Q1
$109K Buy
+21,770
New +$138K 0.05% 80
2024
Q4
Sell
-37,868
Closed -$233K 90
2024
Q3
$233K Sell
37,868
-5,000
-12% -$33.9K 0.09% 84
2024
Q2
$285K Sell
42,868
-53,357
-55% -$394K 0.15% 78
2024
Q1
$980K Sell
96,225
-19,000
-16% -$193K 0.48% 46
2023
Q4
$1.3M Sell
115,225
-4,750
-4% -$19.8K 0.7% 34
2023
Q3
$312K Hold
119,975
0.17% 72
2023
Q2
$424K Buy
119,975
+43,000
+56% +$193K 0.22% 65
2023
Q1
$325K Sell
76,975
-3,705
-5% -$44K 0.2% 56
2022
Q4
$1.33M Sell
80,680
-148,320
-65% -$1.67M 0.9% 29
2022
Q3
$2.92M Sell
229,000
-106,180
-32% -$1.57M 1.89% 19
2022
Q2
$3.92M Buy
335,180
+19,180
+6% +$118K 2.34% 13
2022
Q1
$1.92M Buy
316,000
+35,300
+13% +$260K 0.84% 35
2021
Q4
$2.57M Buy
280,700
+41,500
+17% +$441K 1.04% 28
2021
Q3
$2.71M Buy
239,200
+93,450
+64% +$1.14M 1.19% 24
2021
Q2
$1.44M Buy
+145,750
New +$1.99M 0.51% 42

Other funds holding ALT

DCF Advisers's ALT Position: Q2 2026 in Review

DCF Advisers held its Altimmune (ALT) position steady in Q2 2026 at 14,700 shares worth $44.7K. The position accounts for 0.01% of the portfolio, ranked #93.

DCF Advisers first reported a position in ALT in Q2 2021 and has held it in 19 quarters since. The position peaked at $3.92M in Q2 2022. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • DCF Advisers held 14,700 shares of Altimmune worth $44.7K as of Q2 2026.
  • DCF Advisers left its Altimmune share count unchanged in Q2 2026.
  • Altimmune made up 0.01% of DCF Advisers's portfolio in Q2 2026, its #93 holding.
  • DCF Advisers first reported a position in Altimmune in Q2 2021 and has held it in 19 quarters since.
  • DCF Advisers's Altimmune position peaked at $3.92M in Q2 2022.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.